Celularity, Inc. (NASDAQ:CELU) Short Interest Update

Celularity, Inc. (NASDAQ:CELU) was the recipient of a large increase in short interest in August. As of August 31st, there was short interest totaling 1,897,722 shares, an increase of 370.2% from the August 15th total of 403,568 shares. Based on an average trading volume of 21,797,628 shares, the short-interest ratio is currently 0.1 days. Currently, 7.9% of the company’s shares are short sold.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. XTX Topco Ltd lifted its holdings in shares of Celularity by 106.4% in the 2nd quarter. XTX Topco Ltd now owns 21,452 shares of the company’s stock valued at $42,000 after purchasing an additional 11,057 shares during the last quarter. Acadian Asset Management LLC acquired a new stake in shares of Celularity in the first quarter valued at approximately $34,000. Geode Capital Management LLC grew its position in shares of Celularity by 15.0% during the fourth quarter. Geode Capital Management LLC now owns 160,190 shares of the company’s stock worth $178,000 after acquiring an additional 20,876 shares during the last quarter. Bank of America Corp DE grew its position in shares of Celularity by 1,538.1% during the second quarter. Bank of America Corp DE now owns 37,300 shares of the company’s stock worth $73,000 after acquiring an additional 35,023 shares during the last quarter. Finally, Jane Street Group LLC acquired a new position in shares of Celularity in the 4th quarter valued at $46,000. 19.02% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, Weiss Ratings upgraded shares of Celularity from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, August 27th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company has an average rating of “Sell”.

Celularity Stock Performance

Shares of NASDAQ:CELU traded down $0.03 on Friday, hitting $1.41. 96,695 shares of the company’s stock were exchanged, compared to its average volume of 12,236,725. Celularity has a 1-year low of $0.56 and a 1-year high of $2.55. The company has a market capitalization of $40.81 million, a PE ratio of -0.42 and a beta of 0.79. The firm’s 50-day moving average is $0.97 and its 200 day moving average is $1.01.

Celularity Company Profile

Celularity, Inc is a clinical-stage biotechnology company focused on the development of allogeneic, placenta-derived cell therapies and exosome-based biologics for oncology, regenerative medicine and immune-driven conditions. Utilizing a proprietary platform that harnesses the unique properties of postpartum placental cells, the company aims to create off-the-shelf therapies that can be administered without the need for tissue matching or conditioning regimens.

The company’s pipeline includes a range of natural killer (NK) cell products, mesenchymal-like placental stromal cells and exosome formulations designed to modulate inflammatory responses and target tumor cells.